PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–May 28, 2015–

Tyrogenex, a privately held company focused on the development of next-generation targeted therapeutics for cancer and ophthalmology, today announced the release of one abstract for X-82 to be presented as a poster during the 2015 American Society for Clinical Oncology (ASCO) annual meeting held in Chicago May 29 through June 2.

X-82 in combination with docetaxel to measure change in vascular parameters and proliferation:

Title: Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel
Poster Session: Saturday, May 30, 8 a.m. – 11:30 a.m., Developmental Therapeutics-Clinical Pharmacology and Experimental Therapeutics
Abstract Number: TPS2601
Poster Board Number: 317a
Location: S Hall A
Presenter: Justine Bruce, M.D., Carbone Cancer Center, University of Wisconsin, Madison, WI

About Tyrogenex
Tyrogenex is developing X-82, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1 single agent study show that X-82 is well tolerated and did not exhibit any dose-limiting toxicity during the study.

In oncology, VEGFR tyrosine kinase inhibitors, such as X-82, typically have demonstrated benefit in a variety of cancers though dosage, and use of this class in combination with other therapies, has been limited by side effects. Phase 1 data show that X-82 could a have a significantly lower toxicity profile, which may make it an ideal candidate for combination therapy.

For ophthalmology, the company has initiated a phase 2 study known as “APEX,” for wet AMD in Previously treated Eylea patients with X-82. The study is designed to evaluate the safety and efficacy of X-82 in the prevention of vision loss due to wet AMD. A phase 1 study showed X-82 was able to maintain or improve vision in all subjects who received the drug for the six-month study duration and most subjects did not require any rescue injections during that time. There were no dose-limiting toxicities encountered during the study.

Corporate Contact:
Tyrogenex
Teri Swift, 561-727-9559
Corporate Communications
teri@tyrogenex.com
or
Media Contact:
LaVoie Health Science
David Connolly, 617-374-8800 ext. 108
dconnolly@lavoiehealthscience.com

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Learn more about membership.

Author
Topics